MedPath

Tianjin Medical University Cancer Institute & Hospital

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer

Phase 1
Conditions
Pancreatic Cancer Stage III
Pancreatic Cancer Stage IV
Interventions
Other: GPBSC
First Posted Date
2017-08-02
Last Posted Date
2017-08-02
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
30
Registration Number
NCT03236883
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC

Not Applicable
Completed
Conditions
Esophageal Cancer
Interventions
First Posted Date
2017-07-19
Last Posted Date
2019-12-04
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
20
Registration Number
NCT03222440
Locations
🇨🇳

Department of Radiation Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China

Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer

Phase 2
Conditions
Colon Cancer Liver Metastasis
Interventions
Procedure: TACE
Device: eluting-bead
First Posted Date
2017-06-05
Last Posted Date
2017-06-27
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
200
Registration Number
NCT03175016
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma

Phase 2
Conditions
Differentiated Thyroid Carcinoma
Interventions
First Posted Date
2017-05-30
Last Posted Date
2017-05-30
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
20
Registration Number
NCT03167385
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma

Phase 2
Completed
Conditions
Soft Tissue Sarcoma, Adult, Stage IIB
Interventions
Drug: Placebo
Drug: AIM regimen / GT regimen
First Posted Date
2017-04-20
Last Posted Date
2019-12-26
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
52
Registration Number
NCT03121833
Locations
🇨🇳

Tianjin Medical University Cancer Hospital & Institute, Tianjin, Tianjin, China

Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy

Phase 2
Conditions
Soft Tissue Sarcoma, Adult, Stage II
Interventions
First Posted Date
2017-04-20
Last Posted Date
2017-05-22
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
80
Registration Number
NCT03121846
Locations
🇨🇳

Tianjin Medical University Cancer Hospital & Institute, Tianjin, Tianjin, China

The Exploratory Study of Electroacupuncture in the Treatment of Peripheral Neuropathy Induced by Platinum Based Chemotherapy Drugs

Not Applicable
Conditions
Chemotherapy-induced Peripheral Neuropathy
First Posted Date
2017-02-09
Last Posted Date
2018-02-12
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
72
Registration Number
NCT03048591

Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)

Phase 2
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2017-02-08
Last Posted Date
2017-02-08
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
30
Registration Number
NCT03046979
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Evaluation of Pcv-aCO2 in the Fluid Treatment of Abdominal Tumor Patients After Surgery

Not Applicable
Conditions
Abdominal Tumor
Abdominal Infection
First Posted Date
2016-11-30
Last Posted Date
2016-11-30
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
150
Registration Number
NCT02977429
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

A Phase II Trial to Compare Efficacy and Safety of CRT VS Neo-CRT in Patients Who Achieved CCR for Esophageal Cancer

Phase 2
Conditions
Stage III Esophageal Cancer
Stage II Esophageal Cancer
First Posted Date
2016-11-09
Last Posted Date
2017-07-18
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
40
Registration Number
NCT02959385
Locations
🇨🇳

Department of Radiation Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath